These three movers and shakers in innovation are ones to know going into this week. Courtesy photos

This week's Houston innovators to know covers all the bases, from a freshly started startup to one that closed a multimillion-dollar raise. Here's who in Houston innovation that you need to know.

Joe Alapat, CEO of Liongard

Houston-based Liongard has fresh funds thanks to a $4.5 million round. Courtesy of Liongard

Joe Alapat has something to celebrate. His Houston-based startup, Liongard — an Information Technology automation and management company — closed its Series A round of funding with an oversubscribed $4.5 million.

"This investment will help us accelerate development and integrations to create additional visibility across the varied technology stacks that MSPs [or, managed service provider] support," says Alapat in a release. "Our true goal is to support MSPs across the entire client journey — automating onboarding, documentation, and insight that speeds up issue resolution — unleashing teams to operate at 10X." Read the full story here.

Marissa Limsiaco, CEO of Tenavox

This month, InnovationMap is profiling the faces of Pride within innovation. Marissa Limsiaco, CEO of Tenavox, discusses her career and the company's expansion plans. Courtesy of Tenavox

Though Marissa Limsiaco actually resides down Highway 290 in Austin, her company, Tenavox, has some of its operations here. The commercial real estate-finding tech tool is growing, and Limsiaco is among the ones to credit for Tenavox's success. She discussed the growth plans — including the plan to enter the Dallas market by the end of the year — in a special Pride Month series. Read the Q&A here.

Ryan Schwartz, CEO and founder of Mental Health Match

Ryan Schwartz realized online dating was easier than finding a therapist. He created a tool to change that. Courtesy of Mental Health Match

When you're in great need for a therapist, the worst thing you have to do go through the process to actually find someone you can count on. It's a tiring process to discover a new therapist who meshes well with you and has the capabilities for what you need. Ryan Schwartz created Mental Health Match to pair up patient to professional — and it's designed to be free for those who need it most: The patient. Check out the story here.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”